Shandong Suncadia Medicine Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS25
PHASE 3 / 2-39
RECRUITING20
READOUTS ≤12 MONTHS8
READOUT SLIPPED >6 MO36%
Delay Index: of 11 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Shandong Suncadia Medicine Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| HRS-1893 NCT06516068 |
P2 | Active, not recruiting | Obstructive Hypertrophic Cardiomyopathy | 42 | 2024-11-18 |
| HRS-8080; Dalpiciclib Isethionate Tablets NCT06167694 |
P1/2 | Recruiting | Unresectable or Metastatic Breast Cancer | 146 | 2026-06 (+7 mo) |
| HRS-1301 NCT07229937 |
P2 | Recruiting | Hyperlipidemia | 189 | 2026-08 |
| HRS-1893 Tablets NCT07021976 |
P3 | Active, not recruiting | Obstructive Hypertrophic Cardiomyopathy | 228 | 2026-09 |
| HRS-2129 Tablet NCT07706777 |
P2 | Recruiting | Acute Gouty Arthritis | 90 | 2026-10 |
| HRS-2189 NCT06679036 |
P1/2 | Recruiting | Advanced Unresectable or Metastatic Breast Cancer | 300 | 2026-10-30 |
| HRS-1780 Tablets NCT07470983 |
P2 | Active, not recruiting | Primary Aldosteronism | 61 | 2026-11 |
| HRS-7535 tablet NCT06820099 |
P2 | Recruiting | Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity | 225 | 2026-12 |
| HRS-7085 NCT07229950 |
P2 | Recruiting | Adult Patients With Moderately to Severely Active Ulcerative Colitis | 48 | 2026-12 (+9 mo) |
| HRS-7058 + SHR-1316 NCT06915142 |
P2 | Recruiting | Advanced Malignant Tumour | 300 | 2026-12 |
| HRS-5346 NCT07767513 |
P2 | Recruiting | Lipoprotein Disorder | 60 | 2027-02 |
| HRS-1893 Tablet NCT07269717 |
P2 | Recruiting | Heart Failure With Preserved Ejection Fraction | 48 | 2027-03 |
| HRS-7058 NCT07032077 |
P2 | Recruiting | Solid Tumors | 100 | 2027-06 (+12 mo) |
| HRS-8080 Tablet NCT07024173 |
P3 | Recruiting | Locally Advanced Breast Cancer; Metastatic Breast Cancer | 240 | 2027-08 (+8 mo) |
| HRS-6719 NCT06922357 |
P1/2 | Recruiting | Advanced/Metastatic Solid Tumors | 120 | 2027-12 |
| HRS-7535 NCT07528027 |
P3 | Recruiting | Hypertension With Overweight or Obesity | 648 | 2027-12 |
| HRS-1893 Tablet NCT07021963 |
P2 | Recruiting | Hypertrophic Cardiomyopathy | 300 | 2027-12 |
| HRS-7058 NCT07601048 |
P3 | Not yet recruiting | KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment | 450 | 2028-05 |
| HRS-6208 Capsule NCT07389733 |
P1/2 | Recruiting | Advanced Unresectable or Metastatic Breast Cancer of Adults | 180 | 2028-12 |
| HRS-8080 Tablet ; Dalpiciclib Isethionate NCT07354022 |
P3 | Recruiting | Locally Advanced or Metastatic Breast Cancer | 912 | 2028-12 |
| HRS-7058 NCT07589569 |
P2 | Recruiting | Pancreatic Cancer | 92 | 2028-12 |
| HRS-1780 tablet NCT07708441 |
P2/3 | Recruiting | Uncontrolled or Resistant Hypertension | 914 | 2029-04 |
| HRS-1780 tablets NCT07419828 |
P3 | Recruiting | Chronic Kidney Disease | 5386 | 2030-04 |
| HRS-8080 Tablets NCT07349069 |
P3 | Recruiting | Breast Cancer | 5500 | 2030-12 |
| RENEW-CKD NCT07625774 |
P3 | Not yet recruiting | Chronic Kidney Disease | 3690 | 2031-05 |